Business context and reporting period
Sana Biotechnology, Inc. is a preclinical-stage biotechnology company developing engineered-cell medicines using ex vivo and in vivo platforms. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2022. The company had no approved products, product revenue, or clinical trials underway; all candidates remained preclinical.
Financial performance and position
Amounts below are in millions of dollars except per-share data. No meaningful product margins are reported because Sana has not generated revenue.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $76.7 | $53.2 | $222.0 | $140.1 |
| Total operating expenses | $86.2 | $83.4 | $190.8 | $245.6 |
| Net loss | $85.1 | $83.3 | $189.0 | $245.2 |
| Net loss per share, diluted | $0.45 | $0.46 | $1.01 | $1.53 |
| Cash used in operating activities | Not separately provided | Not separately provided | $214.0 | $141.0 |
- At September 30, cash and cash equivalents were $163.3 million, marketable securities were $348.2 million, and restricted cash was $10.5 million. Cash, cash equivalents, and marketable securities totaled $511.6 million, down from $746.9 million at December 31, 2021.
- Current assets were $500.3 million and current liabilities $114.8 million. Total liabilities were $332.1 million and stockholders’ equity $566.0 million.
- Sana reported no debt outstanding. Operating lease liabilities totaled $111.8 million; undiscounted operating lease obligations were $223.6 million.
- For the nine months, investing activities provided $122.1 million, chiefly reflecting maturities exceeding purchases of marketable securities; property and equipment purchases were $16.3 million. Financing activities provided $3.9 million, including $0.7 million net proceeds from the ATM offering.
Material changes versus the prior comparable period
- Quarterly R&D expense increased $23.5 million year over year, primarily from personnel, research and laboratory work, third-party manufacturing, and facility costs. For nine months, R&D rose $81.8 million to $222.0 million.
- Nine-month net loss declined $56.2 million year over year, but this was not driven by lower core R&D spending. Results included a $79.4 million non-cash gain from revaluation of success-payment and contingent-consideration liabilities, versus $67.8 million of expense in the prior-year period.
- Operating cash use increased $73.0 million to $214.0 million for nine months, despite the lower reported net loss, reflecting non-cash fair-value changes and operating cash requirements.
- General and administrative expense increased $10.5 million for nine months to $48.2 million. It included a $4.5 million write-off of construction-in-progress costs related to the Fremont manufacturing facility.
- Accumulated other comprehensive loss from unrealized marketable-securities losses increased to $6.4 million from $1.4 million at year-end 2021.
Outlook, management commentary, and risks
- Management stated that existing cash, cash equivalents, and marketable securities were expected to fund working capital and capital expenditures for at least 12 months from the filing’s operating-plan assessment. Sana also expected losses and expenses to rise as research, clinical preparation, and manufacturing activities expanded, and anticipated needing additional financing in the future.
- At the filing date, Sana said it remained on track to submit an IND for SC291 in 2022. It described SC276 as potentially entering IND stage as early as 2023 and SC451 as early as 2024, with potential clinical data from these programs in 2024.
- Management reported a second-generation manufacturing process for in vivo CAR T candidate SG295 with at least a 50-fold improvement in product potency. A decision disclosed for Q4 2022 was to use that process in first-in-human studies, delaying the SG295 IND to 2023. This is a post-quarter development described in the filing.
- The company moved its planned manufacturing facility from Fremont, California, to Bothell, Washington. The Bothell lease covers approximately 79,565 square feet for an initial 16-year term; Sana said internal manufacturing there could take several years to begin. It intended to sublease or terminate the Fremont lease.
- An ATM facility permits up to $150 million of common-stock sales; only about $0.7 million net had been raised by September 30, 2022. Further equity financing could dilute shareholders; debt or collaborations could impose other costs or constraints.
- Key risks include unproven technologies and preclinical safety/efficacy uncertainty; regulatory and clinical delays; complex manufacturing and dependence on CDMOs and limited suppliers; facility buildout and technology-transfer risk; inflation and supply-chain disruption; competition for specialized staff; and potential COVID-19 effects. The company reported modest pandemic-related delays in discovery and development activities.
- Fair-value remeasurements can materially swing reported expenses and losses. At September 30, the Cobalt contingent-consideration liability was $141.1 million and the Cobalt and Harvard success-payment liabilities together were $35.7 million. These are estimates subject to significant assumptions; success payments had not been triggered.
- No material legal proceedings were reported. Management concluded disclosure controls and procedures were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether SC291’s 2022 IND target was met, and the subsequent timing and development status of SC295, SC276, and SC451.
- Whether the stated cash runway remains valid as operating cash use, capital spending, and manufacturing commitments evolve; review later financing and ATM activity.
- Progress, costs, and timing for the Bothell manufacturing buildout and any sublease or termination of the Fremont facility.
- The drivers and assumptions behind the sizable non-cash revaluation gains and liabilities, including potential milestone and success-payment obligations.
- Whether preclinical results, manufacturing readiness, supply availability, regulatory feedback, and clinical plans support management’s projected timelines.